Relmada Therapeutics, Inc.
NASDAQ:RLMDBiotechnology
-$0.06 today
- Market cap
- $304.61M
- Beta
- 0.39
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$0.68
Volume 1.86M
Average 1.24M
RLMD Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Relmada Therapeutics, Inc.NASDAQ: RLMD
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $19.05M (cash outflow) rose 8.5% year over year, ahead of the -22.2% change in trailing-twelve-month net income. Sequentially, it fell 4.1% from the prior quarter. Over 3 fiscal years it compounded at -28.5% a year.
Context
- Net income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$31.58M (-45.0%) for the fiscal year ending Dec 2026, a slowdown from the -28.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$19.05M-4.1% QoQ
- Last fiscal yearDec 2025
- -$57.39M-28.3% YoY
- LTMMar 2026
- -$58.88M-22.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +8.5% | +69.8% | +61.3 pp |
| 1 year | -28.3% | -45.0% | -16.7 pp |
| 3-year CAGR | -28.5% | -12.6% | +15.9 pp |
| 5-year CAGR | -21.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (57.39M) USD
- Year-over-year change
- +28.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (57.39M) | +28.3% |
| FY2024 | 2024-12-31 | (79.98M) | +19.0% |
| FY2023 | 2023-12-31 | (98.79M) | +37.1% |
| FY2022 | 2022-12-31 | (157.04M) | -24.9% |
| FY2021 | 2021-12-31 | (125.75M) | — |
Net Income vs competitors
How RLMD compares with its peers on the latest reported figures
- RLMD's LTM Mar 2026 net income of $58.88M is the 8th largest of the 9 companies compared; the peer median is $90.81M.
- Its year-over-year change of -22.2% is the 8th highest of 9, against a peer median of +1.4%.
- Over three fiscal years its annual growth of -28.5% compares with a peer median of +18.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $124.31M | -5.5% | +25.1% | 1360.6% | |
| LTM Mar 2026 | $108.83M | -7.2% | +18.7% | — | |
| LTM Mar 2026 | $104.29M | +8.2% | -6.9% | — | |
CBUSCibus, Inc. | LTM Mar 2026 | $103.27M | -65.4% | +96.0% | 2409.4% |
| LTM Mar 2026 | $102.15M | +215.2% | -46.4% | 154.4% | |
| LTM Mar 2026 | $78.34M | +28.7% | +2.0% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $77.27M | -7.7% | +35.7% | — |
| LTM Mar 2026 | $58.88M | -22.2% | -28.5% | — | |
| LTM Mar 2026 | $37.1M | +163.8% | — | 14.5% | |
| Peer median (excluding RLMD) | $90.81M | +1.4% | +18.7% | 757.5% | |
Competitors are the stored peer set for RLMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (125.75M) | (157.04M) | (98.79M) | (79.98M) | (57.39M) |
| Depreciation & Amortization | 1.26K | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 40.49M | 44.19M | 43.81M | 30.19M | 14.96M |
| Change in Working Capital | (7.86M) | 10.59M | 3.08M | (1.58M) | (3.95M) |
| Accounts Receivables | 79.46K | (426.06K) | 512.43K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.85M | 421.04K | (1.76M) | 624.55K | (2.56M) |
| Other Working Capital | (10.79M) | 10.6M | 4.32M | (2.21M) | (1.39M) |
| Other Non-Cash Items | 1.25M | (1.55M) | 241.16K | (381.66K) | 586.18K |
| Operating Cash Flow | (91.87M) | (103.8M) | (51.66M) | (51.76M) | (45.79M) |
| Capital Expenditures | 0 | 0 | (4) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (222.98M) | (47.29M) | (90.46M) | (12.08M) | (83.83M) |
| Sales of Investments | 168.86M | 67.03M | 140.92M | 63.64M | 35.69M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (54.12M) | 19.73M | 50.45M | 51.56M | (48.14M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 185.31M | 42.73M | 0 | 246.75K | 93.64M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.63M | 2.29M | (98.46K) | (287.09K) | (73.02K) |
| Financing Cash Flow | 187.94M | 45.02M | (98.46K) | (40.34K) | 93.56M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 41.95M | (39.05M) | (1.3M) | (234.54K) | (360.49K) |
| Free Cash Flow | (91.87M) | (103.8M) | (51.66M) | (51.76M) | (45.79M) |
Relmada Therapeutics, Inc.
NASDAQ:RLMD
Intrinsic Alpha fair value
Locked
Current Price
$2.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.